JNJ

Johnson & Johnson
Pharmaceuticals · Health Care · as of 2026-11-20
Last close
$271.60
+1.7% on the session
1-year return
+37.2%
+17.1% over six months
Volatility
21.3%
annualized, trailing year
Max drawdown
-11.0%
worst peak to trough, 1y
What the numbers say

Johnson & Johnson is a pharmaceuticals name in the health care sector. Over the past year it returned +37.2%, against -0.0% over three months and +1.5% over one. It trades 8.9% above its 200-day average, so the longer trend is confirming recent strength. Annualized volatility of 21.3% is moderate by single-stock standards.

Its worst peak-to-trough decline over the year was -11.0%, and it has traded a median $1.7B a day, the figure that decides whether a position can actually be entered and exited at posted prices. Its daily moves correlate -0.02 with the S&P 500 proxy, so it has been moving substantially on its own.

Where it ranks
Within Health Care#22 of 59
Stronger than 64% of its sector on the momentum profile
Across the whole index#107 of 497

How JNJ scores on all four profiles

Its standing on steadiness, defensiveness and rebound, plus the factor-by-factor breakdown behind each score, and its closest and least-correlated peers among 6 others in Pharmaceuticals.

Start a free 7-day trial
Full metrics
1 day+1.7%
1 week-5.0%
1 month+1.5%
3 months-0.0%
6 months+17.1%
1 year+37.2%
12-1 momentum+35.2%
Volatility (1y, annualized)21.3%
Max drawdown (1y)-11.0%
Distance vs 200-day average+8.9%
Return per unit of risk1.74
Median daily dollar volume$1.7B
Free newsletter

Get JNJ when it shows up in a ranking

Two editions a weekday, free, ranked lists built from this same data, on whatever the market is talking about.

Everything on this page is computed from daily adjusted closing prices. It contains no earnings, balance-sheet, guidance or ownership data, and it is not a valuation. Nothing here is tailored to your circumstances or a recommendation to buy or sell. Past performance does not predict future results.